US EditionVivodyne Secures $40M Series A to Revolutionize Drug Discovery with Lab-Grown Human Tissues
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Vivodyne Secures $40M Series A to Revolutionize Drug Discovery with Lab-Grown Human Tissues
SAN FRANCISCO, CA & PHILADELPHIA, PA — Vivodyne has raised $40 million in Series A funding to expand its cutting-edge robotics and AI platform, which uses lab-grown human tissues to transform preclinical drug testing. The funding, led by Khosla Ventures with contributions from investors such as Lingotto Investment Management and Helena Capital, supports a new 23,000-square-foot fully robotic lab at Genesis Marina in South San Francisco. Vivodyne…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
